ChemoCentryx Inc. (NASDAQ:CCXI) saw an upside of 4.18% on Monday to $40.01 after adding $1.6. The 5-day average trading volume is 34,290,988 shares of the company’s common stock. It has gained $42.16 in the past week. An average of 10,102,917 shares of the company has been traded in the last 20 days, and the 50-day average volume stands at 4,772,241.
CCXI’s 1-month performance is 140.21% or $23.93 on its low of $15.15 reached on 09/13/21. The company’s shares have touched a 52-week low of $9.53 and high of $70.29, with the stock’s rally to the 52-week high happening on 02/09/21. YTD, CCXI has lost -37.97% or -$22.57. However, the current price is down -43.07%% from the 52-week high price.
3 Tiny Stocks Primed to Explode The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
On May 21, 143 days have gone by since the last insider trading activity for ChemoCentryx Inc. (CCXI). Tyree James L (Director) most recently sold 2,454 shares at $9.76 per share on May 21. This transaction cost the insider $23,956. Director, Parker Geoffrey M., sold 30,000 shares at a price of $56.38 on Mar 05. Then, on Mar 04, Director Parker Geoffrey M. sold 1,910 shares at a price of $60.20 per share. This transaction amounted to $114,980.
ChemoCentryx Inc. (CCXI) has a trailing price-to-earnings (P/E) ratio of 34.65 for the broader industry and 32.57 for the sector. The company’s PE ratio for the last five years has touched a high of 50.56 and a low of 16.39. CCXI stock has a beta of 1.41. Moving on to other valuation ratios, the trailing price-to-sales (P/S) ratio is 63.43 while the price-to-book (PB) in the most recent quarter is 8.12.
ChemoCentryx Inc.’s quick ratio for the period ended June 29 was 5.70, with the current ratio over the same period at 5.70 meaning that CCXI stock is able to fulfill its debt obligations. As well, the company’s long term debt to equity for the quarter ending June 29 was 0.04, while the total debt to equity was 0.07The trailing 12-month EBITDA margin is -80.77%. The firm’s gross profit as reported stood at $120.07 million against revenue of $64.89 million.
For the quarterly period ending June 29 this year, ChemoCentryx Inc.’s cash and short-term investments amounted to $235.4 million against total debt of $71.7 million. Net income and sales went down compared to those figures reported in the previous quarter. Analysts expected CCXI to announce -$0.54 per share in earnings in its latest quarter, but it posted -$0.56, representing a -3.70% surprise. EBITDA for the quarter stood at more than -$37.16 million. CCXI stock balance sheet for the quarter ending June 29 shows that total liabilities totaled 137.4 million, with total debt at $71.7 million. Shareholders hold equity totaling $69.9 million
Let’s look briefly at ChemoCentryx Inc. (CCXI) price momentum from a technical analysis perspective. The 9-day relative strength index as at close on 08 October was 92.73% to suggest the stock is trending Overbought, with historical volatility in this time period at 340.74%.
The stock’s 5-day moving average is $26.99, reflecting a +112.59% or $20.84 change from its current price. CCXI is currently trading +147.33% above its 20-day SMA, +295.08% above its 100-day SMA. However, the stock’s current price level is away from the SMA50 and SMA200 by +166.24% and -36.08% respectively.
Stochastic %K and %D was 82.14% and 72.88% and the average true range (ATR) pointed at 3.99. The RSI (14) points at 90.27%, while the 14-day stochastic is at 88.94% with the period’s ATR at 2.99. The stock’s 9-day MACD Oscillator is pointing at 9.29 and 10.96 on the 14-day charts.
In the most recent analyst report for ChemoCentryx Inc. (NASDAQ: CCXI), SVB Leerink upgraded it to an Outperform rating. They previously had a Mkt perform rating on the stock. Analysts offering their rating for CCXI stock have a consensus rating for the stock as Overweight. Currently, 1 brokerage advisors rate CCXI as a “sell,”, while 1 advise that investors “Hold.” 0 analysts have rated the stock as underweight. 0 rates the stock as overweight while 6 have offered a “buy” rating.
What is CCXI’s price target for the next 12 months?
Analysts have a consensus price target ranging from a low of $14.00 and a high of $107.00, with their median price target at $60.00. Looking at these predictions, the average price target given by analysts is for ChemoCentryx Inc. (CCXI) stock is $62.00.